LDR (LDRH) and Cardiovascular Systems (CSII) Head-To-Head Analysis

Cardiovascular Systems (NASDAQ: CSII) and LDR (NASDAQ:LDRH) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, profitability, earnings and institutional ownership.

Insider & Institutional Ownership

74.2% of Cardiovascular Systems shares are held by institutional investors. 3.3% of Cardiovascular Systems shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.


This table compares Cardiovascular Systems and LDR’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cardiovascular Systems -1.62% -0.51% -0.31%
LDR -18.02% -16.37% -13.65%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Cardiovascular Systems and LDR, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardiovascular Systems 1 4 1 0 2.00
LDR 0 0 0 0 N/A

Cardiovascular Systems currently has a consensus target price of $26.50, indicating a potential upside of 16.02%.

Earnings and Valuation

This table compares Cardiovascular Systems and LDR’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cardiovascular Systems $204.91 million 3.70 -$1.79 million ($0.10) -228.38
LDR N/A N/A N/A ($0.71) N/A

LDR has lower revenue, but higher earnings than Cardiovascular Systems. Cardiovascular Systems is trading at a lower price-to-earnings ratio than LDR, indicating that it is currently the more affordable of the two stocks.


Cardiovascular Systems beats LDR on 8 of the 9 factors compared between the two stocks.

About Cardiovascular Systems

Cardiovascular Systems, Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications. Its peripheral artery disease (PAD) systems are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee. Its products include Diamondback 360 Peripheral Orbital Atherectomy System (OAS) (Diamondback 360 Peripheral), the Stealth 360 OAS (Stealth 360), Diamondback 360 Peripheral, Diamondback 360 60cm Peripheral, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral and Diamondback 360 2.00 Peripheral. The Company’s coronary arterial disease (CAD) product, Diamondback 360 Coronary OAS (Coronary OAS), is marketed as a treatment for severely calcified coronary arteries.

About LDR

LDR Holding Corporation is a medical device company. The Company focuses on designing and commercializing surgical technologies for the treatment of patients suffering from spine disorders. The Company’s primary products are based on its VerteBRIDGE fusion and Mobi non-fusion platforms, both of which are designed for applications in the cervical and lumbar spine. The Company’s VerteBRIDGE products are designed around its plating technology that enables surgeons to implant VerteBRIDGE devices with direct visualization of the disc and to affix the devices to the vertebrae from inside the spinal disc space. The Company’s Mobi non-fusion platform is underlined by Mobi-C, a cervical disc replacement device with a mobile bearing core that is designed to replicate the natural anatomical movement of the spine by facilitating independent bending and twisting similar to a healthy disc. The Company’s traditional fusion products include Easyspine, MC+, ROI, ROI-T, SpineTune and C-Plate.

Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply